thalidomide has been researched along with Radiculopathy in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Radiculopathy: Disease involving a spinal nerve root (see SPINAL NERVE ROOTS) which may result from compression related to INTERVERTEBRAL DISK DISPLACEMENT; SPINAL CORD INJURIES; SPINAL DISEASES; and other conditions. Clinical manifestations include radicular pain, weakness, and sensory loss referable to structures innervated by the involved nerve root.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Song, T | 1 |
| Ma, X | 1 |
| Gu, K | 1 |
| Yang, Y | 1 |
| Yang, L | 1 |
| Ma, P | 1 |
| Wang, W | 1 |
| Zhao, J | 1 |
| Yan, R | 1 |
| Guan, J | 1 |
| Wang, C | 1 |
| Qi, Y | 1 |
| Ya, J | 1 |
| Manning, DC | 1 |
| Gimbel, J | 1 |
| Wertz, R | 1 |
| Rauck, R | 1 |
| Cooper, A | 1 |
| Zeldis, JB | 1 |
| Levinsky, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy[NCT00120120] | Phase 2/Phase 3 | 181 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thalidomide and Radiculopathy
| Article | Year |
|---|---|
A Phase II Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Lenalidomide in Lumbar Radicular Pain with a Long-Term Open-Label Extension Phase.
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Immunologic Factors; Lenalidomide; Lumbosacral Reg | 2017 |
1 other study available for thalidomide and Radiculopathy
| Article | Year |
|---|---|
Thalidomide represses inflammatory response and reduces radiculopathic pain by inhibiting IRAK-1 and NF-κB/p38/JNK signaling.
Topics: Animals; Cells, Cultured; Humans; Inflammation; Interleukin-1 Receptor-Associated Kinases; Male; MAP | 2016 |